Andreas Kuhn, PhD

Andreas Kuhn has worked in the field of RNA biochemistry and molecular biology for more than thirty years. His work on mRNA-based immunotherapies began in 2007 in the academic group of Ugur Sahin at the University Clinic Mainz, and Andreas joined BioNTech SE shortly after its founding in 2008. In his current role as Senior Vice President RNA Biochemistry & CMC Management the main focus is expanding proprietary technologies to increase the efficacy of mRNA-based therapies and to optimize GMP-compatible manufacturing processes for RNA. He has co-authored numerous publications and patents ranging from basic research on RNA to its application as a therapeutic agent.